Please login to the form below

Not currently logged in
Email:
Password:

Xeljanz

This page shows the latest Xeljanz news and features for those working in and with pharma, biotech and healthcare.

FDA considers new safety warnings for Pfizer’s JAK inhibitor Xeljanz

FDA considers new safety warnings for Pfizer’s JAK inhibitor Xeljanz

Post-marketing study shows increased risk of serious heart-related problems and cancer with Xeljanz. ... In addition, 122 patients receiving Xeljanz treatment developed cancer, versus 42 for those taking TNF inhibitors.

Latest news

More from news
Approximately 20 fully matching, plus 64 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story
How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?
The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19
The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...

Infographics